文献速递神经肿瘤神经重症

脑膜瘤术后病因特异性生存:全国性竞争风险研究

Cause-Specific Survival After Meningioma Surgery: A Nationwide Population-Based Competing Risk Study.
PubMed 文献 · World Neurosurg · 2020-10-20

基于法国国家健康数据系统,采用竞争风险模型分析脑膜瘤手术患者的病因特异性死亡。年龄、合并症指数、脊髓位置、脑脊液分流、肿瘤分级、复发再手术和进展性肿瘤为独立预后因素。

要点

  • 脑膜瘤术后1-3年相关死亡风险约2.4%-3.1%。
  • 脊髓位置与较低死亡风险相关(SHR 0.2),脑脊液分流与较高风险相关(SHR 3.13)。
  • 复发再手术未改善结局,推荐使用竞争风险模型进行脑膜瘤研究。

核心结论

  • 脑膜瘤术后病因特异性生存在年轻、低合并症、脊髓及良性脑膜瘤成人中较高。
  • 颅内、进展性恶性脑膜瘤需脑脊液分流且整体健康状况差者,脑膜瘤相关死亡风险显著增加。
  • 复发再手术未能改善结局。
  • 推荐在无关死亡可能较大的脑膜瘤研究中使用竞争风险模型,以获得更准确的疾病风险及相关预测因素估计。

研究设计与样本

  • 全国性人口基竞争风险研究,使用法国Système National des Données de Santé数据库,通过结合手术类型和国际疾病分类的算法检索脑膜瘤病例。
  • 主要终点为脑膜瘤相关死亡的累积发生率,采用竞争风险分析识别与脑膜瘤特异性死亡相关的因素。

主要发现

  • 脑膜瘤相关死亡风险在1年时为2.4%(95%CI 2-2.7),2年时为3%(95%CI 2.6-3.4),3年时为3.1%(95%CI 2.7-3.6)。
  • 调整Fine-Gray竞争风险回归显示,手术时年龄(SHR 1.07,95%CI 1.05-1.09,P < 0.001)、死亡率相关疾病指数(SHR 1.68,95%CI 1.07-2.63,P = 0.025)、费用相关疾病指数(SHR 1.06,95%CI 1.03-1.09,P < 0.001)、脊髓位置(SHR 0.2,95%CI 0.08-0.47,P < 0.001)、脑脊液分流(SHR 3.13,95%CI 1.9-5.16,P < 0.001)、分级(SHR 1.88,95%CI 1.13-3.14,P = 0.015)、复发再手术(SHR 1.6,95%CI 1.01-2.51,P = 0.043)和进展性脑膜瘤(SHR 2.87,95%CI 1.23-6.68,P = 0.015)是脑膜瘤相关死亡的独立预后因素。

临床怎么用

  • 对于脑膜瘤手术患者,应评估年龄、合并症、肿瘤位置、分级及是否需脑脊液分流等预后因素。
  • 复发再手术可能无法改善病因特异性生存,需谨慎决策。
  • 在脑膜瘤临床研究中采用竞争风险模型可更准确评估疾病风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Survival after meningioma surgery often is reported with inadequate allowance for competing causes of death. METHODS: We processed the French Système National des Données de Santé database using an algorithm combining the type of surgical procedure and the International Classification of Diseases to retrieve appropriate cases of meningiomas. The cumulative incidence of meningioma-related death was the primary end point. A competing risk analysis was performed to identify factors associated with meningioma-specific death of patients who underwent meningioma surgery. RESULTS: The risk of meningioma-related death at 1, 2, and 3 years respectively was 2.4%, 95% confidence interval [CI] 2-2.7; 3%, 95% CI 2.6-3.4; and 3.1%, 95% CI 2.7-3.6. In the adjusted Fine-Gray competing risk regression for meningioma cause-specific survival, age at surgery (subdistribution hazard ratio [SHR] 1.07, 95% CI 1.05-1.09, P < 0.001), mortality-related morbidity index (SHR 1.68, 95% CI 1.07-2.63, P = 0.025), expenditure-related morbidity index (SHR 1.06, 95% CI 1.03-1.09, P < 0.001), spinal location (SHR 0.2, 95% CI 0.08-0.47, P < 0.001), cerebrospinal fluid shunt (SHR 3.13, 95% CI 1.9-5.16, P < 0.001), grade (SHR 1.88, 95% CI 1.13-3.14, P = 0.015) redo surgery for recurrence (SHR 1.6, 95% CI 1.01-2.51, P = 0.043), and progressing meningioma (SHR 2.87, 95% CI 1.23-6.68, P = 0.015) were established as independent prognostic factors of meningioma-related death. CONCLUSIONS: Cause-specific survival after meningioma surgery is greater in younger, low-comorbidity adults with spinal and benign meningioma. Those with an intracranial, progressing malignant tumor requiring cerebrospinal fluid shunting and having a severe global health-state have a significant increased risk of meningioma-related death. Redo surgery failed to improve the outcome. We recommend the use of competing risk model in meningioma studies in which unrelated mortality may be substantial, as this approach results in more accurate estimates of disease risk and associated predictors.

来源:World Neurosurg,查看原文。版权归原作者所有。

引用

  1. Champeaux-Depond C, Constantinou P, Weller J, et al. Cause-Specific Survival After Meningioma Surgery: A Nationwide Population-Based Competing Risk Study. World Neurosurg. 2020. PMID: 33096279. doi:10.1016/j.wneu.2020.10.012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。